PolyPid Ltd reports results for the quarter ended December 31 - Earnings Summary

PolyPid Advances D-PLEX₁₀₀ Toward FDA Review as Q1 2026 Loss Narrows and Debt Is Retired

PolyPid Q1 FY26 net loss narrows 7.61% to $7.7 million

PolyPid Q1 EPS $(0.35) Beats $(0.43) Estimate

PolyPid Ltd - U.S. Commercial Partnership Discussions for D-Plex100 in Late Stages

Press Release: PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

Calendar of U.S. Earnings Expected in the Week Ahead

PolyPid Ltd expected to post a loss of 43 cents a share - Earnings Preview

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Roth MKM Remains a Buy on PolyPid (PYPD)

PolyPid says SHIELD II data show D-PLEX100 doxycycline release lasts up to 32 days

PolyPid starts trading on Frankfurt Stock Exchange under 2PV, adding to Nasdaq listing

PolyPid director Yitzhak Jacobovitz files initial beneficial ownership statement

PolyPid files Form 3 disclosing director Robert Benjamin Stein holdings

PolyPid Begins FDA NDA Submission for D-PLEX₁₀₀ to Prevent Surgical Infections

Wall Street Analysts Are Bullish on Top Healthcare Picks

PolyPid’s Moment Is Here: NDA Submission Begins as a High-Impact Catalyst Stack Takes Shape (NASDAQ: PYPD)

BRIEF-Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA

PolyPid Ltd - U.S. Commercialization Partnership Negotiations for D-Plex₁₀₀ on Track